Oric Pharmaceuticals Inc. (ORIC) News

Oric Pharmaceuticals Inc. (ORIC): $3.64

0.05 (+1.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ORIC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 380

in industry

Filter ORIC News Items

ORIC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ORIC News Highlights

  • ORIC's 30 day story count now stands at 9.
  • Over the past 5 days, the trend for ORIC's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • The most mentioned tickers in articles about ORIC are NOV and ASH.

Latest ORIC News From Around the Web

Below are the latest news stories about ORIC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORIC as an investment opportunity.

ORIC Pharmaceuticals to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 5:35 p.m. GMT.

GlobeNewswire | November 8, 2022

ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update

Initial Phase 1b data for three ongoing clinical studies expected to be reported in 1H 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

GlobeNewswire | November 7, 2022

ORIC Pharmaceuticals GAAP EPS of -$0.63 misses by $0.07 (NASDAQ:ORIC)

ORIC Pharmaceuticals press release (ORIC): Q3 GAAP EPS of -$0.63 misses by $0.07.Cash, cash equivalents and investments totaled $218.0 million as of September 30, 2022, which the…

Seeking Alpha | November 7, 2022

ORIC Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Update

Initial Phase 1b data for three ongoing clinical studies expected to be reported in 1H 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer Ongoing clinical development of ORIC-114 expanded with FDA clearance of US IND Preclinical data on ORIC-533 to be presented at the 64th American Society of Hematology (ASH) Annual Meeting Cash and investments of $218.0 million expected to fund current operating plan into 2H 2024 SOUTH SAN FRANCISCO, Calif

Yahoo | November 7, 2022

ORIC Pharmaceuticals to Present Preclinical Data on CD73 Inhibitor Program in Multiple Myeloma at the 64th American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a preclinical poster presentation on ORIC-533 at the 64th American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022, in New Orleans, LA. Details of the poster presentation are as follows: Title: CD73 Inhibition Reverses

Yahoo | November 3, 2022

Bullish insiders at ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) loaded up on US$2.1m of stock earlier this year

Over the last year, a good number of insiders have significantly increased their holdings in ORIC Pharmaceuticals, Inc...

Yahoo | October 22, 2022

AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition

AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.

Yahoo | October 21, 2022

ORIC Pharmaceuticals (ORIC) Stock: Poster Child For The Current Downturn In Biotech

ORIC is a speculative Buy. Key risks include disappointing data for phase 1 readouts 1H23, delays in the clinic and heavy competition in certain areas. Read more.

Seeking Alpha | October 14, 2022

GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults

GSK's pivotal phase III AReSVi-006 study evaluating its respiratory syncytial virus (RSV) vaccine candidate in adults aged 60 years and above met its primary endpoint.

Yahoo | October 14, 2022

BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance

If approved, BioMarin's (BMRN) valoctocogene roxaparvovec will become the first gene therapy for treating hemophilia A in the United States. A decision from the FDA is due on Mar 31, 2023.

Yahoo | October 13, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.452 seconds.